Anemia Criteria Assist Decision on Type of Colorectal Cancer Screen

THURSDAY, Jan. 3, 2019 -- In patients without broad-definition anemia and/or abdominal mass, flexible sigmoidoscopy (FS), instead of colonoscopy, may suffice to rule out colorectal cancer, according to a study published online Dec. 19 in the British...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsIn this Phase 2 KSCC 1602 trial of bevacizumab plus FTD/TPI, the primary endpoint of PFS was achieved. This combination therapy showed favorable survival outcomes with an acceptable safety profile for elderly patients with previously untreated metastatic colorectal cancer.Clinical trial identificationUMIN000025241.Legal entity responsible for the studyKyushu Study group of Clinical Cancer.FundingTaho Pharmaceutical.DisclosureA. Makiyama: Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lily Pharmaceutical; Speaker Bureau / Expert testimony: Chugai Pharmaceutical; Speaker Bureau / Expert testimony: ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPembro in combination with mFOLFOX7 or FOLFIRI was safe and tolerable in patients with mCRC.Clinical trial identificationNCT03374254; Release date: December 15, 2017.Editorial acknowledgementJacqueline Kolston, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA); Funded by Merck Sharp&Dohme Corp., a subsidiary of Merck&Co., Inc., Kenilworth, NJ, USA.Legal entity responsible for the studyMerck Sharp&Dohme Corp., a subsidiary of Merck&Co., Inc., Kenilworth, NJ, USA, and Array BioPharma.FundingMerck Sharp&Dohme Corp., a subsidiary of Merck&Co., Inc., Kenilworth, NJ, USA, and Array Bi...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundMTL-CEBPA is a first-in-class small activating RNA (saRNA) oligonucleotide which specifically up-regulates the myeloid cell master regulator, C/EBP- α (CCAAT/enhancer-binding protein alpha).MethodsWe conducted a phase I, 3  + 3 dose escalation and dose expansion trial of MTL-CEBPA in adults with HCC or secondary liver cancer. Patients received intravenous MTL-CEBPA at 28-160 mg/m2 for 3 weeks either QW, BIW at d1 and d2, BIW at d1 and d3, or TIW at d1, d2, and d3 followed by a rest period of 1 week. Adverse even ts (AEs), serum PK, WBC biomarkers and anti-tumour activity were as...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIntravenous administrations of ISU104 were well tolerated up to 20  mg/kg/day without DLT, and showed disease control rate of 60.0%. Safety and efficacy of ISU104 as mono- or combination-therapy and potential biomarkers will be further explored in head and neck, colorectal and breast cancers.Clinical trial identificationNCT03552406.Legal entity responsible for the studyISU Abxis.FundingKDDF: Korea Drug Development Fund.DisclosureB. Keam: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: MSD; Advisory / Consultancy: Genexin; Research grant / Funding (self): ONO; Research grant / Funding (self): ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe KRASG12C mutation occurs in ∼13% of lung cancers (11% of non-small cell lung cancer [NSCLC]), 3% of colorectal cancer (CRC) and appendix cancers, and 1–3% of other solid tumors. KRASG12C is a driver of tumorigenesis, but there are no approved therapies targeting this mutation. AMG 510, a novel, orally administered small molecule, specifically and irreversibly inhibits KRASG12C by locking it in an inactive GDP-bound state. A phase 1, first-in-human, open-label, multicenter study is underway to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510 in adult patients ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe oral small molecule AXL kinase inhibitor TP-0903 is well tolerated with a manageable safety profile. Hematologic toxicity was observed as a DLT. Future studies will evaluate the role of TP0903 in selected disease cohorts as monotherapy and in combination. Serum soluble AXL will be evaluated as a potential predictive biomarker of response.Clinical trial identificationNCT: 02729298.Legal entity responsible for the studyTolero Pharmaceuticals, Inc.FundingTolero Pharmaceuticals, Inc.DisclosureJ. Sarantopoulos: Research grant / Funding (institution): Tolero. G. Fotopoulos: Research grant / Funding (institution): ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis is the first study evaluating a PRMT5 inhibitor. Overall, AEs were common but manageable. Patients with multiple tumor types responded to therapy. Part 2 of the study is open for subjects with predefined solid tumors and non-Hodgkin ’s lymphoma.Clinical trial identificationNCT02783300.Legal entity responsible for the studyGlaxoSmithKline.FundingGlaxoSmithKline.DisclosureL.L. Siu: Advisory / Consultancy: Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca/Medimmune (compensated), Morphosys (compensated), Roche (compensated), GeneSeeq (compensated), Loxo (compensated), Oncorus ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe MTD of FLU was 150mg BID in advanced solid malignancies. FLU demonstrated single-agent antitumour activity in BC and OC, particularly in platinum-sensitive and BRCAMut OC.Clinical trial identificationNCT03509636.Legal entity responsible for the studyHuiping Li.FundingJiangsu Hengrui Medicine Co.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsBiweekly administration of TAS-102 and BV prevents neutropenia and could be one of the treatment options for 3rd line chemotherapy for mCRC.Clinical trial identificationUMIN000030030. 2018/March/01.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
By STEVEN MERAHN, MD In 1807, in an effort to spite the British and French for shipping interference (and forced recruitment of American citizens into military service), the United States Congress passed an Embargo Act, effectively shutting down trade with these two countries. Britain and France quickly found other trading partners; the US, then limited in our capacity to sell products outside our borders, was left with a devastated economy and a gaping hole in our face. It took only weeks before Congress passed a loophole; they repealed the act within 15 months of its passing. It was a great lesson in unintended co...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Politics Uncategorized Health care debate Health Care Reform Steven Merahn universal healthcare Source Type: blogs
More News: Anemia | Cancer | Cancer & Oncology | Colonoscopy | Colorectal Cancer | Pharmaceuticals | Sigmoidoscopy | Study | UK Health